Loading data for AIDX — first visit, this takes a few seconds.
20/20 Biolabs, Inc. (AIDX)
NasdaqCM: AIDX
· Real-Time Price · USD
0.62
+0.00 (0.00%)
At close: Aug 28, 2026, 8:00 PM
0.63
+1.47%
After-hours: 7:49 PM
The price, the headline numbers and the latest news, in one place.
20/20 Biolabs, Inc. (AIDX) Stock Price, Analysis & Data
No data available
| Bid | 0.61 |
| Market Cap | 7.97M |
| Revenue (ttm) | 2.04M |
| Net Income (ttm) | -7.12M |
| 0.00 | |
| -0.58 | |
| n/a | |
| n/a | |
| P/B (ttm) | 4.73 |
| P/S (ttm) | 3.91 |
| Earnings Date | n/a |
| Ask | 1 |
| Volume | 120,514 |
| Avg. Volume (20D) | 644,908 |
| Open | 0.61 |
| Previous Close | 0.62 |
| Day's Range | 0.61 - 0.67 |
| 52-Week Range | 0.40 - 50.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AIDX
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known...
Industry Medical Devices
Sector Healthcare
IPO Date Feb 19, 2026
Employees 4
Stock Exchange NasdaqCM
Ticker Symbol AIDX
Website https://2020biolabs.com
Financial Performance
In 2025, 20/20 Biolabs's revenue was 2.05M, an increase of 16.71% compared to the previous year's 1.75M. Earnings were -3.74M, a decrease of -32.65%.
Financial StatementsEarnings Surprise
20/20 Biolabs has released their quarterly earnings on Aug 14, 2026:
- Revenue of $353.38K misses estimates by $0, with Infinity% YoY growth.
- EPS of -0.26 misses estimates by -0.14, with -Infinity% YoY decline.
